Phenotarget Biosciences, Inc., a California based company, is developing first-in-class therapeutics as anti-viral treatment of the COVID-19 viral infection. Leveraging technology developed at Texas A&M, Phenotarget has rights to create a peptide-based drug discovery platform that can potentially be applied toward many therapeutic targets for unmet medical needs.
